18:51 , Mar 23, 2018 |  BC Week In Review  |  Clinical News

Immuron reports Phase II data for NASH candidate

Immuron Ltd. (ASX:IMC; NASDAQ:IMRN) reported top-line data from a Phase II trial in 133 patients with non-alcoholic steatohepatitis (NASH) showing that a significantly greater proportion of patients who received oral IMM-124E achieved a ≥15% reduction...
00:38 , Feb 3, 2017 |  BC Week In Review  |  Clinical News

Oral DUR-928: Ph Ib data

Data from 20 cirrhotic and non-cirrhotic NASH patients and 12 matched controls with normal liver function in an open-label, Australian Phase Ib trial showed that single doses of low- and high-dose oral DUR-928 dose-dependently reduced...
07:00 , May 16, 2016 |  BC Week In Review  |  Clinical News

Emricasan: Additional Phase II data

Additional data from a U.S. Phase II trial in 86 patients with liver cirrhosis showed that twice-daily 25 mg oral emricasan reduced MELD score by 0.3 points, Child-Pugh score by 0.3 points and total bilirubin...
08:00 , Jan 11, 2016 |  BC Week In Review  |  Clinical News

Emricasan: Phase II data

A double-blind, U.S. Phase II trial in 86 patients with liver cirrhosis showed that twice-daily 25 mg oral emricasan significantly reduced cleaved CK18 levels from baseline to 3 months vs. placebo (reduction of 4.6% vs....
07:00 , Oct 5, 2015 |  BC Week In Review  |  Clinical News

Emricasan: Phase II data

Top-line data from 22 evaluable patients with portal hypertension and compensated liver cirrhosis predominantly due to non-alcoholic steatohepatitis (NASH) or HCV infection in an open-label, U.S. Phase II trial showed that twice-daily 25 mg oral...
07:00 , Sep 28, 2015 |  BioCentury  |  Analyst Picks & Changes

Finance

Finance Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg9/25 clsConatus Pharmaceuticals Inc. (NASDAQ:CNAT)H.C. WainwrightEd ArceNewBuy11%$5.16 Arce initiated coverage with a $15 target, saying that Conatus' emricasan is a "highly differentiated first-in-class" pan-caspase protease inhibitor for liver disease. He said...
07:00 , Jun 11, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: High throughput, single-cell RNA sequencing to identify cells in heterogeneous populations

Assays and screens TECHNOLOGY: Cellular assays A high throughput method for measuring RNA expression could help determine gene expression relationships in individual cells within heterogeneous cell populations. In tissue-derived single-cell suspensions, the method tags each cell with...
07:00 , May 4, 2015 |  BC Week In Review  |  Clinical News

Emricasan: Additional Phase II data

Additional data from a double-blind, U.S. Phase II trial in 38 patients with NAFLD, including patients with non-alcoholic steatohepatitis (NASH), showed that twice-daily 25 mg emricasan led to a median absolute reduction in ALT levels...
07:00 , Mar 30, 2015 |  BC Week In Review  |  Clinical News

Emricasan: Phase II data

Top-line data from a double-blind, U.S. Phase II trial in 38 patients with NAFLD, including patients with non-alcoholic steatohepatitis (NASH), showed that twice-daily 25 mg emricasan met the primary endpoint of reducing ALT levels from...
00:50 , Mar 27, 2015 |  BC Extra  |  Clinical News

Conatus' emricasan meets Phase II endpoint

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) jumped $1 (17%) to $6.76 on Thursday after it said pan-caspase inhibitor emricasan met the primary endpoint of a Phase II trial to treat non-alcoholic fatty liver disease (NAFLD). In the...